New imaging agent radiocaine enters human safety testing

NCT ID NCT07081217

Recruiting now Diagnosis Sponsor: Lutroo Imaging LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests the safety and radiation of Radiocaine, a new radioactive tracer for PET scans. Six healthy adult volunteers will receive an injection and be monitored for side effects and radiation exposure. The goal is to see if Radiocaine can safely light up nerve activity in future imaging studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiocaine (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a new way to see nerve activity in the body using a PET scan.
What could go wrong: This is a very early, tiny trial (6 people) just checking safety and radiation. It may not lead to a useful diagnostic tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Stanford University School of Medicine
RECRUITING

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.